Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Novome Biotechnologies.

    Client Virtual Booth

    NOVOME BIOTECHNOLOGIES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Novome Biotechnologies
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    279 E Grand Ave, Suite 420 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://novomebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/novome-biotechnologies-inc./
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes

    Details:

    The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammatory bowel disease (IBD).


    Lead Product(s): NB1000S,NB2000P

    Therapeutic Area: Gastroenterology Product Name: NOV-001

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Tencent

    Deal Size: $43.5 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing September 13, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

    Details:

    NOV-001 is an investigational combination product composed of NB1000S and NB2000P. Preclinical studies of NOV001 showed consistent and robust reduction in urine oxalate levels in multiple animal models of disease.


    Lead Product(s): NB1000S,NB2000P

    Therapeutic Area: Gastroenterology Product Name: NOV-001

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 17, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease

    Details:

    Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.


    Lead Product(s): Genetically Engineered Microbial Medicines

    Therapeutic Area: Gastroenterology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Genentech

    Deal Size: $605.0 million Upfront Cash: $15.0 million

    Deal Type: Collaboration November 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

    Details:

    The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.


    Lead Product(s): Undisclosed

    Therapeutic Area: Nephrology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Partner/Sponsor/Collaborator: DCVC Bio

    Deal Size: $33.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing January 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search